https://orcid.org/0009-0007-1733-9640
References
- Carbon M, Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. Dialogues Clin Neurosci. 2014;16(4):505–524. doi:10.31887/DCNS.2014.16.4/mcarbon
- Howes OD, McCutcheon R, Agid O, et al. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry. 2017;174(3):216–229. doi:10.1176/appi.ajp.2016.16050503
- Kane JM, Kishimoto T, Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. World Psychiatry. 2013;12(3):216–226. doi:10.1002/wps.20060
- Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:217047. doi:10.1155/2015/217047
- US Food and Drug Administration. Enrichment Strategies for Clinical Trials to Support Demonstration of Effectiveness of Human Drugs and Biological Products. Silver Spring, Maryland: FDA; 2019.
- Bugarski-Kirola D, Bitter I, Liu IY, Abbs B, Stankovic S. ENHANCE: Phase 3, randomized, double-blind, placebo-controlled study of adjunctive pimavanserin for schizophrenia in patients with an inadequate response to antipsychotic treatment. Schizophr Bull Open. 2022;3(1). doi:10.1093/schizbullopen/sgac006
- Bugarski-Kirola D, Arango C, Fava M, et al. Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE Phase 2 randomised, placebo-controlled trial in North America and Europe. Lancet Psychiatry. 2022;9(1):46–58. doi:10.1016/S2215-0366(21)00386-2
- Yaegashi H, Kirino S, Remington G, Misawa F, Takeuchi H. Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta-analysis. CNS Drugs. 2020;34(6):579–598. doi:10.1007/s40263-020-00713-9
- Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiatry. 2006;67(7):1114–1123. doi:10.4088/jcp.v67n0715
- Lang K, Federico V, Muser E, Menzin J, Menzin J. Rates and predictors of antipsychotic non-adherence and hospitalization in medicaid and commercially-insured patients with schizophrenia. J Med Econ. 2013;16(8):997–1006. doi:10.3111/13696998.2013.816310
- Rabinovitch M, Bechard-Evans L, Schmitz N, Joober R, Malla A. Early predictors of nonadherence to antipsychotic therapy in first-episode psychosis. Can J Psychiatry. 2009;54(1):28–35. doi:10.1177/070674370905400106
- Stentzel U, van den Berg N, Schulze LN, et al. Predictors of medication adherence among patients with severe psychiatric disorders: findings from the baseline assessment of a randomized controlled trial (Tecla). BMC Psychiatry. 2018;18(1):155. doi:10.1186/s12888-018-1737-4
- Baros AM, Latham PK, Moak DH, Voronin K, Anton RF. What role does measuring medication compliance play in evaluating the efficacy of naltrexone? Alcohol Clin Exp Res. 2007;31(4):596–603. doi:10.1111/j.1530-0277.2007.00343.x
- Brannan S. 32.2 two global phase III trials of encenicline for cognitive impairment in chronic schizophrenia patients: red flags and lessons learned. Schizophr Bull. 2019;45(Suppl 2):S141–S2. doi:10.1093/schbul/sbz022.133
- De Las Cuevas C, de Leon J. Self-report for measuring and predicting medication adherence: experts’ experience in predicting adherence in stable psychiatric outpatients and in pharmacokinetics. Patient Prefer Adherence. 2020;14:1823–1842. doi:10.2147/PPA.S242693
- Higashi K, Medic G, Littlewood KJ, Diez T, Granström O, De Hert M. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3(4):200–218. doi:10.1177/2045125312474019
- Shahin W, Kennedy GA, Stupans I. The impact of personal and cultural beliefs on medication adherence of patients with chronic illnesses: a systematic review. Patient Prefer Adherence. 2019;13:1019–1035. doi:10.2147/PPA.S212046